BCL2 and neoplasm: NFs inhibit head and neck squamous cell carcinoma (HNSCC) tumor growth and target B-cell lymphoma-2 (BCL2) expression in vivo through the transfer of exosomes containing miR-3188, which are significantly reduced with the transition to CAFs [117].